Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

MicuRx Lands $9.6 Million to Fund China Trials of Antibiotic

publication date: Oct 24, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
MicuRx Pharma, a US-China clinical-stage biopharma, formed a JV with Shanghai Zhangjiang Biomedical Industry Venture Capital. Shanghai Zhangjiang invested 60 million RMB ($9.6 million) in the JV, and MicuRx contributed China rights to its lead antibiotic candidate. MRX-I is a novel, oral oxazolidinone antibiotic that is designed to be effective against antibiotic-resistant infections. MicuRx, which located its China facilities in Zhangjiang Park, will use the money to fund China Phase II and III clinical trials of MRX-I. MicuRx presented at ChinaBio®’s first Investor Forum, held in 2007. More details...

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...